Type I IFN‐mediated synergistic activation of mouse and human DC subsets by TLR agonists

• Published in: European journal of immunology Vol. 45; no. 10; pp. 2798 - 2809
• Main Authors: Kreutz, Martin, Bakdash, Ghaith, Dolen, Yusuf, Sköld, Annette E., Hout‐Kuijer, Maaike A., Vries, I. Jolanda M., Figdor, Carl G.
• Format: Journal Article
• Language: English
• Published: Germany Wiley Subscription Services, Inc 01.10.2015
• Subjects: Adjuvants ⋅ Dendritic cells ⋅ Synergy ⋅ Toll‐like receptors ⋅ Type I IFN; Animals; Dendritic Cells - cytology; Dendritic Cells - immunology; Humans; Interferon Type I - immunology; Medicin och hälsovetenskap; Membrane Glycoproteins - agonists; Membrane Glycoproteins - immunology; Mice; Rodents; Th1 Cells - cytology; Th1 Cells - immunology; Toll-Like Receptor 3 - immunology; Toll-Like Receptor 7 - agonists; Toll-Like Receptor 7 - immunology; Adjuvants ⋅ Dendritic cells ⋅ Synergy ⋅ Toll-like receptors ⋅ Type I IFN
• ISSN: 0014-2980; 1521-4141; 1521-4141
• DOI: 10.1002/eji.201545583

Novel approaches of dendritic cell (DC) based cancer immunotherapy aim at harnessing the unique attributes of different DC subsets. Classical monocyte‐derived DC vaccines are currently being replaced by either applying primary DCs or specifically targeting antigens and adjuvants to these subsets in vivo. Appropriate DC activation in both strategies is essential for optimal effect. For this purpose TLR agonists are favorable adjuvant choices, with TLR7 triggering being essential for inducing strong Th1 responses. However, mouse CD8α+ DCs, considered to be the major cross‐presenting subset, lack TLR7 expression. Interestingly, this DC subset can respond to TLR7 ligand upon concurrent TLR3 triggering. Nevertheless, the mechanism underlying this synergy remains obscure. We now show that TLR3 ligation results in the production of IFN‐α, which rapidly induces the expression of TLR7, resulting in synergistic activation. Moreover, we demonstrate that this mechanism conversely holds for plasmacytoid DCs that respond to TLR3 ligation when TLR7 pathway is mobilized. We further demonstrate that this mechanism of sharpening DC senses is also conserved in human BDCA1+ DCs and plasmacytoid DCs. These findings have important implications for future clinical trials as it suggests that combinations of TLR ligands should be applied irrespective of initial TLR expression profiles on natural DC subsets for optimal stimulation.